Arteriovenous fistula (AVF) dysfunction causes significant morbidity in maintenance hemodialysis (MHD) patients. This study investigated the association between the gut-derived uremic toxin Trimethylamine-N-oxide (TMAO) and AVF failure risk.
Methods:
Baseline serum TMAO was measured in 164 MHD patients with functional AVFs. The primary endpoint over a 24-month follow-up was the first AVF dysfunction event. We utilized optimal cut-point determination, Kaplan-Meier survival analysis, and Cox proportional hazards models.
Results:
Over 24 months, 43 patients (26.2%) experienced AVF dysfunction. The optimal TMAO cut-point was 278.74 μmol/L. High TMAO (>278.74 μmol/L) correlated with significantly earlier AVF dysfunction (log-rank p = 0.030) and remained an independent predictor of AVF failure after multivariable adjustment (HR, 2.07; 95% CI, 1.04–4.13; p = 0.035).
Discussion:
Elevated baseline TMAO is an independent risk factor for AVF dysfunction. Serum TMAO >278.74 μmol/L serves as a novel prognostic risk stratifier identifying MHD patients at high risk for vascular access failure.
LiyanageTNinomiyaTJhaV, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet2015; 385(9981): 1975–1982.
2.
ChenTSunXTsueiS, et al. Care for end-stage kidney disease in China: progress, challenges, and recommendations. Lancet Reg Health West Pac2025; 54: 101268.
3.
LokCEHuberTSLeeT, et al. KDOQI Clinical Practice Guideline for vascular access: 2019 update. Am J Kidney Dis2020; 75(4 Suppl. 2): S1–S164.
4.
Chinese Society of Nephrology. Guidelines for dialysis access in China (2024). Chin J Nephrol2024; 40(12): 990–1070.
5.
KimHJLeeHKimDK, et al. Recurrent vascular access dysfunction as a novel marker of cardiovascular outcome and mortality in hemodialysis patients. Am J Nephrol2016; 44(1): 71–80.
6.
KuoTHLuCLChangYH, et al. Association of dysfunction of vascular access for hemodialysis with major adverse cardiovascular events – a group-based trajectory model analysis. Circ J2020; 84(6): 1004–1011.
7.
AllonMOrntDBSchwabSJ, et al. Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Kidney Int2000; 58(5): 2178–2185.
8.
SchmidliJWidmerMKBasileC, et al. Editor’s choice – vascular access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg2018; 55(6): 757–818.
9.
LanoGSalléeMPelletierM, et al. Mean platelet volume predicts vascular access events in hemodialysis patients. J Clin Med2019; 8(5): 608.
10.
LinCJPanCFLiuHL, et al. The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis. Atherosclerosis2012; 225(1): 173–179.
11.
WuYWangFWangT, et al. Association of retinol-binding protein 4 with arteriovenous fistula dysfunction in hemodialysis patients. Blood Purif2021; 50(6): 906–913.
12.
IshiiTSuzukiYNakayamaT, et al. Duplex ultrasound for the prediction of vascular events associated with arteriovenous fistulas in hemodialysis patients. J Vasc Access2016; 17(6): 499–505.
13.
BrahmbhattARemuzziAFranzoniM, et al. The molecular mechanisms of hemodialysis vascular access failure. Kidney Int2016; 89(2): 303–316.
14.
LimYJSidorNATonialNC, et al. Uremic toxins in the progression of chronic kidney disease and cardiovascular disease: mechanisms and therapeutic targets. Toxins (Basel)2021; 13(2): 142.
15.
HuCZhangYBiX, et al. Correlation between serum trimethylamine-N-oxide concentration and protein energy wasting in patients on maintenance hemodialysis. Ren Fail2022; 44(1): 1669–1676.
16.
ZhengYTangZYouL, et al. Trimethylamine-N-oxide is an independent risk factor for hospitalization events in patients receiving maintenance hemodialysis. Ren Fail2020; 42(1): 580–586.
17.
ZhangPZouJZChenJ, et al. Association of trimethylamine N-Oxide with cardiovascular and all-cause mortality in hemodialysis patients. Ren Fail2020; 42(1): 1004–1014.
18.
YangSLiXYangF, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol2019; 10: 1360.
19.
DaugirdasJT.Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol1993; 4(5): 1205–1213.
20.
AksoyalpZSErdoganBRAksunS.Optimization of enzyme-linked immunosorbent assay kit protocol to detect trimethylamine N-oxide levels in humans. EXCLI J2023; 22: 263–273.
21.
Working Group of vascular Access Blood Purification Center Branch Chinese Hospital Association. Expert consensus on vascular access for hemodialysis in China (2nd edition). Chin J Blood Purif2020; 36(7): 560–567.
HothornTLausenB.On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal2003; 43(2): 121–137.
24.
BrownTJGimottyPAMamtaniR, et al. Classification and regression trees to predict for survival for patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab. JCO Clin Cancer Inform2024; 8: e2300220.
25.
LeBlancMCrowleyJ.Relative risk trees for censored survival data. Biometrics1992; 48(2): 411–425.
26.
TabbaraMDuqueJCMartinezL, et al. Pre-existing and postoperative intimal hyperplasia and arteriovenous fistula outcomes. Am J Kidney Dis2016; 68(3): 455–464.
27.
Vazquez-PadronRIYuJTabbaraM, et al. Human data first: new biological premises for arteriovenous fistula research. Arterioscler Thromb Vasc Biol2026; 46(3): e323428.
28.
MisraSFuAARajanDK, et al. Expression of hypoxia inducible factor-1α, macrophage migration inhibition factor, matrix metalloproteinase-2 and -9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. J Vasc Interv Radiol2008; 19(2 Pt 1): 252–259.
29.
AsareYSchmittMBernhagenJ.The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. Thromb Haemost2013; 109(3): 391–398.
30.
WasseHHuangRNaqviN, et al. Inflammation, oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients. J Vasc Access2012; 13(2): 168–174.
31.
YamanouchiDTakeiYKomoriK.Balanced mineralization in the arterial system: possible role of osteoclastogenesis/osteoblastogenesis in abdominal aortic aneurysm and stenotic disease. Circ J2012; 76(12): 2732–2737.
32.
WuMRementerCGiachelliCM.Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int2013; 93(4): 365–373.
33.
MartinezLDuqueJCTabbaraM, et al. Fibrotic venous remodeling and nonmaturation of arteriovenous fistulas. J Am Soc Nephrol2018; 29(3): 1030–1040.
34.
ZhuWGregoryJCOrgE, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell2016; 165(1): 111–124.
35.
BoiniKMHussainTLiPL, et al. Trimethylamine-N-oxide instigates NLRP3 inflammasome activation and endothelial dysfunction. Cell Physiol Biochem2017; 44(1): 152–162.
36.
SunXJiaoXMaY, et al. Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome. Biochem Biophys Res Commun2016; 481(1–2): 63–70.
37.
YouLWuYZhengY, et al. Elevated serum interleukin-18 level is correlated with vascular access dysfunction in patients on maintenance haemodialysis. Ann Acad Med Singap2020; 49(3): 119–126.
38.
ZhangXLiYYangP, et al. Trimethylamine-N-oxide promotes vascular calcification through activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) inflammasome and NF-κB (Nuclear Factor κB) signals. Arterioscler Thromb Vasc Biol2020; 40(3): 751–765.
39.
LiJZengQXiongZ, et al. Trimethylamine N-oxide induces osteogenic responses in human aortic valve interstitial cells in vitro and aggravates aortic valve lesions in mice. Cardiovasc Res2022; 118(8): 2018–2030.
40.
BruntVEGioscia-RyanRACassoAG, et al. Trimethylamine-N-oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and healthy humans. Hypertension2020; 76(1): 101–112.
41.
LiZWuZYanJ, et al. Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis. Lab Invest2019; 99(3): 346–357.
42.
TogashiKShinYImamuraY.Non-triple helical form of type IV collagen alpha1 chain suppresses vascular endothelial-cadherin mediated cell-to-cell junctions. J Biochem2022; 172(3): 165–175.
43.
GrossSJWebbAMPeterlinAD, et al. Notch regulates vascular collagen IV basement membrane through modulation of lysyl hydroxylase 3 trafficking. Angiogenesis2021; 24(4): 789–805.
44.
TurnerAWNikpayMSilvaA, et al. Functional interaction between COL4A1/COL4A2 and SMAD3 risk loci for coronary artery disease. Atherosclerosis2015; 242(2): 543–552.
45.
WangXPengXLiuJ, et al. The association of plasma TMAO and body composition with the occurrence of PEW in maintenance hemodialysis patients. Ren Fail2025; 47(1): 2481202.
46.
Heinrich-SanchezYVitalM.Trimethylamine-N-oxide formation, the bacterial taxa involved and intervention strategies to reduce its concentration in the human body. Ann Med2025; 57(1): 2525403.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
